Target Group Inc.
Target Group Inc.
Your view on CBDY
Overview
What the company does, where it operates, and who runs it.
About Target Group Inc.
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- CEO
- Anthony Carlo Zarcone
- Headquarters
- 20 Hempstead Drive, Hamilton, ON, CA
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- CEO
- Anthony Carlo Zarcone
- Headquarters
- 20 Hempstead Drive, Hamilton, ON, CA
Target Group Inc. cultivates, processes, and distributes curated cannabis products for the adult-use medical and recreational cannabis market in Canada.
Its products include cannabis flower and extract pods for vaporizer use, cannabis pre-rolls, k-cup infused coffee and tea pods, infused cannabis beverages and edibles, infused topical products, and CBD wellness products.
The company also offers Wisp, a single-use pre-measured pod and vaporizer system for consumers involved in vaporizing natural herbs, including cannabis.
It has a collaboration agreement with cGreen, Inc for manufacturing and distributing the patent-pending THC antidote True Focus in the United States, Europe, and the Caribbean; and distribution, collaboration, and licensing agreement with Serious Seeds B.V.
The company was formerly known as Chess Supersite Corporation and changed its name to Target Group Inc. in July 2018. The company was incorporated in 2013 and is based in Hamilton, Canada.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Target Group Inc., and the rating behind it. CBDY last traded at $0.0014; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Target Group Inc.. Starting points for Target Group Inc.: beta 1.35 — an Drug Manufacturers - Specialty & Generic name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Target Group Inc.. Target Group Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Target Group Inc.. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Target Group Inc.. Target Group Inc. has reported as a listed company since 2015. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Target Group Inc. valued side by side against its closest peers. Target Group Inc. is measured against Drug Manufacturers - Specialty & Generic peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Target Group Inc., and how their positions are changing. At a $863,836 market value, institutional positions materially move Target Group Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Target Group Inc. executives and directors. Shares of Target Group Inc. have traded between $0.0010 and $0.0030 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Target Group Inc.. Target Group Inc. is a $863,836 Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Target Group Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Target Group Inc.. Coverage tracks Target Group Inc. within Drug Manufacturers - Specialty & Generic (Healthcare). Press releases and market coverage, newest first.